These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 7562966)

  • 1. The impact of newborn screening on cystic fibrosis testing in Victoria, Australia.
    Balnaves ME; Bonacquisto L; Francis I; Glazner J; Forrest S
    J Med Genet; 1995 Jul; 32(7):537-42. PubMed ID: 7562966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
    Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
    Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons learned from 20 years of newborn screening for cystic fibrosis.
    Massie RJ; Curnow L; Glazner J; Armstrong DS; Francis I
    Med J Aust; 2012 Jan; 196(1):67-70. PubMed ID: 22256939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
    Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
    J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience.
    Ranieri E; Lewis BD; Gerace RL; Ryall RG; Morris CP; Nelson PV; Carey WF; Robertson EF
    BMJ; 1994 Jun; 308(6942):1469-72. PubMed ID: 8019280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
    Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM
    J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
    Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF
    Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
    Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
    J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newborn screening for cystic fibrosis in Victoria: 10 years' experience (1989-1998).
    Massie RJ; Olsen M; Glazner J; Robertson CF; Francis I
    Med J Aust; 2000 Jun; 172(12):584-7. PubMed ID: 10914103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A survey of newborn screening for cystic fibrosis in Europe.
    Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
    J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.
    Castellani C; Picci L; Scarpa M; Dechecchi MC; Zanolla L; Assael BM; Zacchello F
    Am J Med Genet A; 2005 Jun; 135(2):142-4. PubMed ID: 15832355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
    Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
    J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
    Barthellemy S; Maurin N; Roussey M; Férec C; Murolo S; Berthézène P; Iovanna JL; Dagorn JC; Sarles J
    Arch Pediatr; 2001 Mar; 8(3):275-81. PubMed ID: 11270251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newborn Screening for Cystic Fibrosis in California.
    Kharrazi M; Yang J; Bishop T; Lessing S; Young S; Graham S; Pearl M; Chow H; Ho T; Currier R; Gaffney L; Feuchtbaum L;
    Pediatrics; 2015 Dec; 136(6):1062-72. PubMed ID: 26574590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neonatal screening for cystic fibrosis: addition of molecular diagnostics to increase specificity.
    Spence WC; Paulus-Thomas J; Orenstein DM; Naylor EW
    Biochem Med Metab Biol; 1993 Apr; 49(2):200-11. PubMed ID: 7683477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
    Parad RB; Comeau AM
    J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for cystic fibrosis in New York State: considerations for algorithm improvements.
    Kay DM; Maloney B; Hamel R; Pearce M; DeMartino L; McMahon R; McGrath E; Krein L; Vogel B; Saavedra-Matiz CA; Caggana M; Tavakoli NP
    Eur J Pediatr; 2016 Feb; 175(2):181-93. PubMed ID: 26293390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk calculations for cystic fibrosis in neonatal screening by immunoreactive trypsinogen and CFTR mutation tests.
    Ogino S; Flodman P; Wilson RB; Gold B; Grody WW
    Genet Med; 2005; 7(5):317-27. PubMed ID: 15915083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
    Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
    J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols.
    Gregg RG; Wilfond BS; Farrell PM; Laxova A; Hassemer D; Mischler EH
    Am J Hum Genet; 1993 Mar; 52(3):616-26. PubMed ID: 7680526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.